Imapemide Does Not Exist as a Recognized Medication
There is no FDA-approved medication called "imapemide" and no clinical evidence supporting its use in medical practice. The term appears to be either a misspelling or confusion with other medications.
Possible Intended Medications
Based on the evidence provided and common clinical scenarios, you may be referring to one of the following:
1. Imipramine Pamoate (Most Likely)
If you meant imipramine pamoate, this is a tricyclic antidepressant (TCA) FDA-approved for depression 1.
Dosing:
- Outpatients: Start 75 mg/day, increase to 150 mg/day (optimal response), maximum 200 mg/day 1
- Hospitalized patients: Start 100-150 mg/day, may increase to 250-300 mg/day 1
- Adolescents/Geriatrics: Start with imipramine hydrochloride tablets 25-50 mg/day (pamoate capsules not available in these strengths), generally unnecessary to exceed 100 mg/day 1
- Can be given once daily at bedtime after tolerance established 1
- Antidepressant effect may take 1-3 weeks 1
Critical Safety Considerations:
- MAOI interaction: At least 14 days must elapse between discontinuing an MAOI and starting imipramine, and vice versa 1
- Anticholinergic effects: Risk of paralytic ileus when combined with other anticholinergic drugs 1
- Drug interactions: Avoid sympathomimetic amines (epinephrine, norepinephrine); potentiates CNS depressants including alcohol 1
- Pregnancy: Use only if clinical benefit clearly justifies fetal risk 1
- Pediatric use: Not recommended due to high unit potency and overdose risk 1
2. Imiquimod
A topical immune response modifier for actinic keratosis treatment 2, 3.
Dosing for 5% cream:
- Apply 3 times weekly for 4 weeks, can repeat for additional 4 weeks 3
- Apply at night, wash off after 8 hours 3
- Complete clearance rate: 50% in meta-analysis 3
Safety: Local skin reactions common but generally well tolerated; careful patient counseling essential 3
3. Imapextide (Investigational)
A GLP-1 receptor antagonist (not agonist) in development for postbariatric hypoglycemia 4.
Status: Phase 1 trials only, not FDA-approved 4
- Dosing studied: 10-200 mg subcutaneously, once weekly 4
- Well tolerated with injection site reactions as most common adverse event 4
Clinical Pitfall
Do not confuse imapextide (GLP-1 antagonist) with GLP-1 agonists like semaglutide or liraglutide used for diabetes and obesity 5, 6, 7. These have opposite mechanisms of action.
Recommendation
Clarify the intended medication name before prescribing. If you meant imipramine pamoate for depression, follow the FDA-approved dosing guidelines above with careful attention to drug interactions and contraindications 1.